Adipokines and the metabolism of key nutrients in patients with obesity


AIM: To study the effect of adipokines on the metabolism of key nutrients in patients with obesity/MATERIAL AND METHODS: Ninety patients aged 18 to 66 years old who were treated at the Department of Preventive and Rehabilitative Nutrition, Research Institute of Nutrition, Russian Academy of Medical Sciences, were examined. Carbohydrate and lipid metabolisms were assessed by turbidimetry and spectrophotometry. The levels of adipokines, insulin, and oxidized low-density lipoproteins (LDL) were measured by ELISA. Insulin resistance was assessed with HOMA-IR in all the patients/RESULTS: It was found that there were discoordinated changes in the content of adipokines. The patients with Grade 1 obesity, as compared to the control group, had a statistically significant decrease in the serum concentrations of adiponectin (5.94±0.90 and 15.34±0.45 µg/ml; p<0.05) and ghrelin (215.50±104.50 and 540.67±0.76 pg/ml; (p<0.05) and resistin levels above the normal values (7.34±1.24 and 5.12±0.22 ng/ml; р<0.05; respectively). There was an inverse correlation between the content of adiponectin and ghrelin, and body mass index in obese patients (r1=-0.25, r2=-0.15; p<0.05). There was evidence that there was also an inverse correlation between the levels of adiponectin, triglycerides, LDL, particularly oxidized LDL (p<0.05). Adipokine-induced insulin resistance appeared as increases in the concentrations of glucose, insulin, and HOMA-IR, as compared to those in the control group/CONCLUSION: A comprehensive approach to evaluating metabolic disorders and adipokine synthesis in obese patients makes it possible to optimize the diagnosis of type 2 diabetes mellitus and cardiovascular diseases and to personalize diet therapy.

Full Text

Restricted Access

About the authors

O O Kirillova


I V Vorozhko

K M Gapparova

Iu G Chekhonina

T B Sentsova

V A Tutel'ian


  1. Ковалева О.Н., Амбросова Т.Н., Ащеулова Т.В., Гетман Е.А. Адипокины: биологические, патофизиологические и метаболические эффекты. Внутренняя мед 2009; 3: 18-26.
  2. Curran J.E., McKay D.R., Winkler A.M. et al. Identification of Pleiotropic Genetic Effects on Obesity and Brain Anatomy. Hum Hered 2013; 75 (2-4): 136-143.
  3. Кравчун П.Г., Кадыкова О.И., Габисония Т.Н. Роль адипоцитокинов в формировании нарушений липидного и углеводного обменов у кардиологических больных. Georgian Med News 2012; 12 (213): 26-30.
  4. Yadav A., Jyoti P., Jain S.K., Bhattacharjee J. Correlation of adiponectin and leptin with insulin resistance: a pilot study in healthy north Indian population. Indian J Clin Biochem 2011; 26 (2): 193-196.
  5. Egecioglu E., Skibicka K.P., Hansson C. et al. Hedonic and incentive signals for body weight control. Rev Endocr Metab Disord 2011; 12 (3): 141-151.
  6. Пальцева Е.М., Константинова С.В., Северин С.Е. Новые биомаркеры: адипонектин в современной диагностике сердечно-сосудистых заболеваний. Кардиол науч-практ журн 2009; 10: 65-74.
  7. Lima M.M., Pareja J.C., Alegre S.M. Visceral fat resection in humans: Effect on insulin sensitivity, beta-cell function, adipokines and inflammatory markers. Obesity 2012; 3 (21): 182-189.
  8. Stastny J., Bienertova-Vasku J., Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012; 6 (2): 120-124.
  9. Castan-Laurell I., Dray C., Knauf C. et al. Apelin, a promising target for type 2 diabetes treatment? Trends Endocrinol Metab 2012; 23 (5): 234-241.
  10. Дедов И.И., Мельниченко Г.А. Ожирение: этиология, патогенез, клинические аспекты. Руководство для врачей. М: Медицинское информационное агентство 2004; 456.
  11. Ginter E., Simko V. Type 2 diabetes mellitus, pandemicin 21st century. Adv Exp Med Biol 2012; 771: 42-50.
  12. Веселовская Н.Г., Чумакова Г.А., Козаренко А.А., Бокслер М.И. Адипокины как корригируемые факторы риска сердечно-сосудистых заболеваний. Рос кардиол науч-практ мед журн 2010; 6: 88-93.



Abstract - 24



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies